Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase NA 14Phase 1 12Phase 1/2 5Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 161Neoplasms 95Prostatic Neoplasms 86Glioblastoma 76Multiple Myeloma 66Pancreatic Neoplasms 64Glioma 62Brain Neoplasms 56Lung Neoplasms 46Carcinoma, Hepatocellular 45Melanoma 44Head and Neck Neoplasms 43Recurrence 42Carcinoma, Non-Small-Cell Lung 41Leukemia, Myeloid, Acute 40Colorectal Neoplasms 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 29Lymphoma 29Carcinoma, Renal Cell 28Polycystic Ovary Syndrome 27Stomach Neoplasms 24Hematologic Neoplasms 23Sarcoma 22Lymphoma, B-Cell 22Endometrial Neoplasms 20Uterine Cervical Neoplasms 19

Interventions

sacubitril and valsartan sodium hydrate drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Carcinoma, Medullary × Clear all
NCT03647657 2022-02-10

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
8 enrolled
EndocrineHead & Neck

Thyroid cancer, medullary, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡